Lexaria Bioscience enters $20M at-the-market equity sales agreement with JonesTrading

Lexaria Bioscience Corp.

Up to $20M of common stock may be sold from time to time through Agent JonesTrading as ATM offering.
Agent will receive 3.0% commission on gross sales price; Company reimburses certain expenses.
Shares sold under previously effective shelf registration statement (File No. 333-262402).
Agreement terminates upon sale of all Shares or earlier termination by either party.
No assurance any Shares will be issued; proceeds used for general corporate purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.